Biomm S.A. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was BRL 118.19 million compared to BRL 104.95 million a year ago. Net loss was BRL 81.14 million compared to BRL 92.56 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.19 BRL | +13.62% | +26.19% | +249.31% |
Apr. 18 | Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil | MT |
Apr. 17 | Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A | CI |
1st Jan change | Capi. | |
---|---|---|
+249.31% | 348M | |
-1.17% | 102B | |
+2.87% | 96.09B | |
+2.13% | 22.28B | |
-14.77% | 21.4B | |
-8.79% | 18.14B | |
-39.98% | 17.02B | |
-13.21% | 16.09B | |
+8.55% | 13.83B | |
+35.75% | 11.97B |
- Stock Market
- Equities
- BIOM3 Stock
- News Biomm S.A.
- Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2023